Combination therapy of IL-21 with PD-1 or CTLA-4 previously showed efficacy in mouse tumour models [202], and an engineered IL-21 fused to a PD-1 antibody showed promising results by providing superior anti-tumour immunity than anti-PD-1 alone in preclinical studies [167]. Here, IL21 is linked to neoplasm.